Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 5, 2011, Pages 1011-1015

  Silvola, Johanna M U ^a   Saraste, Antti ^a   Forsback, Sarita ^a   Laine, V Jukka O ^a   Saukko, Pekka ^b   Heinonen, Suvi E ^c   Ylä Herttuala, Seppo ^c   Roivainen, Anne ^a,b   Knuuti, Juhani ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

atherosclerosis; hypoxia; macrophages; positron emission tomography

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE F 18; APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN RECEPTOR; PIMONIDAZOLE; RADIOPHARMACEUTICAL AGENT; SOMATOMEDIN B; UNCLASSIFIED DRUG; 2-(2-NITRO-1H-IMIDAZOL-1-YL)-N-(2,2,3,3,3-PENTAFLUOROPROPYL)ACETAMIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; ETANIDAZOLE; FLUORINATED HYDROCARBON; FLUORINE; IGF2 PROTEIN, MOUSE; NITROIMIDAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; AORTA; ARTICLE; ATHEROSCLEROTIC PLAQUE; AUTORADIOGRAPHY; CONTROLLED STUDY; DIETARY INTAKE; DISEASE COURSE; DISEASE MARKER; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG UPTAKE; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; WESTERN DIET; ANALYSIS OF VARIANCE; ANIMAL; ANOXIA; ATHEROSCLEROSIS; C57BL MOUSE; DISEASE MODEL; GENETICS; GENOTYPE; METABOLISM; MOUSE MUTANT; PATHOLOGY; SCINTISCANNING; TISSUE DISTRIBUTION;

ANALYSIS OF VARIANCE; ANIMALS; ANOXIA; AORTA; APOLIPOPROTEIN B-100; ATHEROSCLEROSIS; AUTORADIOGRAPHY; DISEASE MODELS, ANIMAL; ETANIDAZOLE; FEMALE; FLUORINE RADIOISOTOPES; GENOTYPE; HYDROCARBONS, FLUORINATED; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR II; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITROIMIDAZOLES; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTORS, LDL; TISSUE DISTRIBUTION;

EID: 79955642031     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.221440     Document Type: Article

References (22)

1. Narula J, Garg P, Achenbach S, Motoyama S, Virmani R, Strauss HW. Arithmetic of vulnerable plaques for noninvasive imaging. Nat Clin Pract Cardiovasc Med. 2008;5:S2-S10.
2. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 2005;25:2054-2061. (Pubitemid 41416300)
3. Bjornheden T, Levin M, Evaldsson M, Wiklund O. Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler Thromb Vasc Biol. 1999;19:870-876. (Pubitemid 29177331)
4. Hulten LM, Levin M. The role of hypoxia in atherosclerosis. Curr Opin Lipidol. 2009;20:409-414.
5. Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Gelpke MDS, Cleutjens JP, van den Akker LH, Corvol P, Wouters BG, Daemen MJ, Bijnens APJ. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol. 2008;51:1258-1265. (Pubitemid 351400903)
6. Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 2-nitroimidazole (EF5) binding predicts radiation resistance in individual 9L sc tumors. Cancer Res. 1996;56:405-411. (Pubitemid 26026372)
7. Komar G, Seppanen M, Eskola O, Lindholm P, Gronroos TJ, Forsback S, Sipila H, Evans SM, Solin O, Minn H. F-18-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med. 2008;49: 1944-1951.
8. Yapp DTT, Woo J, Kartono A, Sy J, Oliver T, Skov KA, Koch CJ, Adomat H, Dragowska WH, Fadzli L, Ruth T, Adam MJ, Green D, Gleave M. Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with F-18-EF5 and positron emission tomography. BJU Int. 2007;99:1154-1161.
9. Ziemer LS, Evans SM, Kachur A, Shuman AL, Cardi CA, Jenkins WT, Karp JS, Alavi A, Dolbier WR, Koch CJ. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole F-18-EF5. Eur J Nucl Med Mol Imaging. 2003;30:259-266. (Pubitemid 36686845)
10. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol. 2009;218:7-29.
11. Koch CJ, Hahn SM, Rockwell K, Covey JM, McKenna WG, Evans SM. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3- pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitrolmidazoles. Cancer Chemother Pharmacol. 2001;48:177-187. (Pubitemid 32758891)
12. Mahy P, De Bast M, Gallez B, Gueulette J, Koch CJ, Scalliet P, Gregoire V. In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors. Radiother Oncol. 2003;67:53-61. (Pubitemid 36570440)
13. Evans SM, Hahn S, Pook DR, Jenkins WT, Chalian AA, Zhang P, Stevens C, Weber R, Weinstein G, Benjamin I, Mirza N, Morgan M, Rubin S, McKenna WG, Lord EM, Koch CJ. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res. 2000;60: 2018-2024. (Pubitemid 30207665)
14. Koch CJ, Evans SM, Lord EM. Oxygen dependence of cellular uptake of Ef5 [2-(2-nitro-1H-imidazol-1-Yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent-antibodies vs bound radioactivity. Br J Cancer. 1995;72:869-874.
15. Minn H, Gronroos TJ, Komar G, Eskola O, Lehtio K, Tuomela J, Seppanen M, Solin O. Imaging of tumor hypoxia to predict treatment sensitivity. Curr Pharm Des. 2008;14:2932-2942.
16. Heinonen SE, Leppanen P, Kholova I, Lumivuori H, Hakkinen SK, Bosch F, Laakso M, Yla-Herttuala S. Increased atherosclerotic lesion calcification in a novel mouse model combining insulin resistance, hyperglycemia, and hypercholesterolemia. Circ Res. 2007;101:1058-1067. (Pubitemid 350084983)
17. Laughlin KM, Evans SM, Jenkins WT, Tracy M, Chan CY, Lord EM, Koch CJ. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1Himidazol- 1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. J Pharmacol Exp Ther. 1996;277: 1049-1057.
18. Haukkala J, Laitinen I, Luoto P, Iveson P, Wilson I, Karlsen H, Cuthbertson A, Laine J, Leppanen P, Yla-Herttula S, Knuuti J, Roivainen A. Ga-68-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice. Eur J Nucl Med Mol Imaging. 2009;36: 2058-2067.
19. Laitinen I, Marjamaki P, Haaparanta M, Savisto N, Laine VJ, Soini SL, Wilson I, Leppanen P, Yla-Herttuala S, Roivainen A, Knuuti J. Nonspecific binding of [(18)F]FDG to calcifications in atherosclerotic plaques: experimental study of mouse and human arteries. Eur J Nucl Med Mol Imaging. 2006;33:1461-1467. (Pubitemid 44885412)
20. Jurrus ER, Weiss HS. Invitro tissue oxygen-tensions in rabbit aortic-arch. Atherosclerosis. 1977;28:223-232. (Pubitemid 8225229)
21. Russell J, Carlin S, Burke SA, Wen B, Yang KM, Ling CC. Immunohistochemical detection of changes in tumor hypoxia. Int J Radiat Oncol Bio Phys. 2009;73:1177-1186.
22. Wilson HM, Barker RN, Erwig LP. Macrophages: promising targets for the treatment of atherosclerosis. Curr Vasc Pharmacol. 2009;7:234-243.